Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 61 articles:
HTML format
Text format



Single Articles


    September 2017
  1. WU T, Li J, Shao L, Xin J, et al
    Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure.
    Gut. 2017 Sep 19. pii: gutjnl-2017-314641. doi: 10.1136/gutjnl-2017-314641.
    PubMed     Text format     Abstract available



  2. Erratum: The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B.
    Gut. 2017;66:1730.
    PubMed     Text format    


    August 2017
  3. HUANG F, Long F, Yu W, Situ J, et al
    High prevalence of hepatitis E virus in semen of infertile male and causes testis damage.
    Gut. 2017 Aug 31. pii: gutjnl-2017-314884. doi: 10.1136/gutjnl-2017-314884.
    PubMed     Text format    


  4. ZHANG W, Sun M, Chen G, An Y, et al
    Reassessment of gamma-glutamyl transpeptidase to platelet ratio (GPR): a large-sample, dynamic study based on liver biopsy in a Chinese population with chronic hepatitis B virus (HBV) infection.
    Gut. 2017 Aug 16. pii: gutjnl-2017-313896. doi: 10.1136/gutjnl-2017-313896.
    PubMed     Text format    


    July 2017
  5. PETTA S, Craxi A
    Can we prevent and modify cardiometabolic disorders by controlling HCV infection?
    Gut. 2017 Jul 13. pii: gutjnl-2017-314505. doi: 10.1136/gutjnl-2017-314505.
    PubMed     Text format    


  6. NASSAL M
    Chronic hepatitis B: divide and conquer?
    Gut. 2017 Jul 13. pii: gutjnl-2017-314255. doi: 10.1136/gutjnl-2017-314255.
    PubMed     Text format    


    June 2017
  7. LEVANDER S, Holmstrom F, Frelin L, Ahlen G, et al
    Immune-mediated effects targeting hepatitis C virus in a syngeneic replicon cell transplantation mouse model.
    Gut. 2017 Jun 23. pii: gutjnl-2016-313579. doi: 10.1136/gutjnl-2016-313579.
    PubMed     Text format     Abstract available


  8. MAHALE P, Engels EA, Li R, Torres HA, et al
    The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.
    Gut. 2017 Jun 20. pii: gutjnl-2017-313983. doi: 10.1136/gutjnl-2017-313983.
    PubMed     Text format     Abstract available


  9. SUN HY, Cheng PN, Tseng CY, Tsai WJ, et al
    Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection.
    Gut. 2017 Jun 14. pii: gutjnl-2017-313832. doi: 10.1136/gutjnl-2017-313832.
    PubMed     Text format     Abstract available


    May 2017
  10. THOMAS E
    Hepatitis B virus X protein: TRIMming antiviral defences in hepatocytes.
    Gut. 2017 May 5. pii: gutjnl-2017-314013. doi: 10.1136/gutjnl-2017-314013.
    PubMed     Text format    


    April 2017
  11. ALLWEISS L, Volz T, Giersch K, Kah J, et al
    Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo.
    Gut. 2017 Apr 20. pii: gutjnl-2016-312162. doi: 10.1136/gutjnl-2016-312162.
    PubMed     Text format     Abstract available


    March 2017
  12. COLPITTS CC, Tawar RG, Mailly L, Thumann C, et al
    Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.
    Gut. 2017 Mar 30. pii: gutjnl-2016-312577. doi: 10.1136/gutjnl-2016-312577.
    PubMed     Text format     Abstract available


  13. LAURAIN A, Kramer L, Sultanik P, Vallet-Pichard A, et al
    Mortality associated with the treatment of HCV with direct-acting antivirals.
    Gut. 2017 Mar 23. pii: gutjnl-2017-313869. doi: 10.1136/gutjnl-2017-313869.
    PubMed     Text format    


  14. HERNAEZ R, Sola E, Moreau R, Gines P, et al
    Acute-on-chronic liver failure: an update.
    Gut. 2017;66:541-553.
    PubMed     Text format     Abstract available


    February 2017
  15. VAN RENNE N, Roca Suarez AA, Duong FH, Gondeau C, et al
    miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis.
    Gut. 2017 Feb 3. pii: gutjnl-2016-312270. doi: 10.1136/gutjnl-2016-312270.
    PubMed     Text format     Abstract available


    January 2017
  16. MENARD A, Aherfi S, Mokhtari S, Dhiver C, et al
    Toward chronic hepatitis C eradication in HIV-positive patients, including those cirrhotic and infected with genotype 3 viruses.
    Gut. 2017 Jan 10. pii: gutjnl-2016-313431. doi: 10.1136/gutjnl-2016-313431.
    PubMed     Text format    


  17. BUDKOWSKA A
    Intriguing structure of the HCV particle.
    Gut. 2017 Jan 5. pii: gutjnl-2016-313184. doi: 10.1136/gutjnl-2016-313184.
    PubMed     Text format    


    December 2016

  18. Erratum: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
    Gut. 2016;65:2060.
    PubMed     Text format    


    November 2016
  19. SUGARMAN J, Revill P, Zoulim F, Yazdanpanah Y, et al
    Ethics and hepatitis B cure research.
    Gut. 2016 Nov 14. pii: gutjnl-2016-313009. doi: 10.1136/gutjnl-2016-313009.
    PubMed     Text format    


  20. ROINGEARD P, Dreneau J, Meunier JC
    Unravelling the multiple roles of apolipoprotein E in the hepatitis C virus life cycle.
    Gut. 2016 Nov 3. pii: gutjnl-2016-312774. doi: 10.1136/gutjnl-2016-312774.
    PubMed     Text format    


    October 2016
  21. YOKOKAWA H, Higashino A, Suzuki S, Moriyama M, et al
    Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a non-human primate model.
    Gut. 2016 Oct 26. pii: gutjnl-2016-312208. doi: 10.1136/gutjnl-2016-312208.
    PubMed     Text format     Abstract available


  22. PIVER E, Boyer A, Gaillard J, Bull A, et al
    Ultrastructural organisation of HCV from the bloodstream of infected patients revealed by electron microscopy after specific immunocapture.
    Gut. 2016 Oct 11. pii: gutjnl-2016-311726. doi: 10.1136/gutjnl-2016-311726.
    PubMed     Text format     Abstract available


    September 2016
  23. KUTTKAT N, Mohs A, Ohl K, Hooiveld G, et al
    Hepatic overexpression of cAMP-responsive element modulator alpha induces a regulatory T-cell response in a murine model of chronic liver disease.
    Gut. 2016 Sep 29. pii: gutjnl-2015-311119. doi: 10.1136/gutjnl-2015-311119.
    PubMed     Text format     Abstract available


  24. CROUCHET E, Lefevre M, Verrier ER, Oudot MA, et al
    Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux.
    Gut. 2016 Sep 8. pii: gutjnl-2015-311289. doi: 10.1136/gutjnl-2015-311289.
    PubMed     Text format     Abstract available


  25. WELZEL TM, Petersen J, Herzer K, Ferenci P, et al
    Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
    Gut. 2016 Sep 7. pii: gutjnl-2016-312444. doi: 10.1136/gutjnl-2016-312444.
    PubMed     Text format     Abstract available


    August 2016
  26. BEILSTEIN F, Lemasson M, Pene V, Rainteau D, et al
    Lysophosphatidylcholine acyltransferase 1 is downregulated by hepatitis C virus: impact on production of lipo-viro-particles.
    Gut. 2016 Aug 31. pii: gutjnl-2016-311508. doi: 10.1136/gutjnl-2016-311508.
    PubMed     Text format     Abstract available


  27. HUTIN YJ, Wiktor SZ
    Prioritising treatment among people who inject drugs in order to eliminate hepatitis C: addressing reluctance with sound economic analyses.
    Gut. 2016 Aug 26. pii: gutjnl-2016-312636. doi: 10.1136/gutjnl-2016-312636.
    PubMed     Text format    


  28. HE GW, Gunther C, Kremer AE, Thonn V, et al
    PGAM5-mediated programmed necrosis of hepatocytes drives acute liver injury.
    Gut. 2016 Aug 26. pii: gutjnl-2015-311247. doi: 10.1136/gutjnl-2015-311247.
    PubMed     Text format     Abstract available


  29. BAYLISS J, Yuen L, Rosenberg G, Wong D, et al
    Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
    Gut. 2016 Aug 17. pii: gutjnl-2015-309300. doi: 10.1136/gutjnl-2015-309300.
    PubMed     Text format     Abstract available


  30. EL-KHAYAT HR, Fouad YM, Maher M, El-Amin H, et al
    Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience.
    Gut. 2016 Aug 10. pii: gutjnl-2016-312012. doi: 10.1136/gutjnl-2016-312012.
    PubMed     Text format     Abstract available


    July 2016
  31. LIU CH, Lin CC, Hsu WC, Chung CY, et al
    Highly bioavailable silibinin nanoparticles inhibit HCV infection.
    Gut. 2016 Jul 19. pii: gutjnl-2016-312019. doi: 10.1136/gutjnl-2016-312019.
    PubMed     Text format     Abstract available


  32. WELZEL TM, Nelson DR, Morelli G, Di Bisceglie A, et al
    Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
    Gut. 2016 Jul 13. pii: gutjnl-2016-311609. doi: 10.1136/gutjnl-2016-311609.
    PubMed     Text format     Abstract available


  33. JENDREK ST, Gotthardt D, Nitzsche T, Widmann L, et al
    Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
    Gut. 2016 Jul 12. pii: gutjnl-2016-311739. doi: 10.1136/gutjnl-2016-311739.
    PubMed     Text format     Abstract available


  34. SHIMAKAWA Y, Bonnard P, El Kassas M, Abdel-Hamid M, et al
    Diagnostic accuracy of the gamma-glutamyl transpeptidase to platelet ratio to predict liver fibrosis in Egyptian patients with HCV genotype 4.
    Gut. 2016 Jul 7. pii: gutjnl-2016-312326. doi: 10.1136/gutjnl-2016-312326.
    PubMed     Text format    


    June 2016
  35. GOUTTENOIRE J, Szkolnicka D, Moradpour D
    Treatment of chronic hepatitis E with ribavirin: lessons from deep sequencing.
    Gut. 2016 Jun 22. pii: gutjnl-2016-312040. doi: 10.1136/gutjnl-2016-312040.
    PubMed     Text format    


  36. STICKEL F, Dubuquoy L
    MicroRNA in alcoholic hepatitis: implications for pathophysiology and treatment.
    Gut. 2016 Jun 1. pii: gutjnl-2016-312101. doi: 10.1136/gutjnl-2016-312101.
    PubMed     Text format    


    May 2016
  37. TODT D, Gisa A, Radonic A, Nitsche A, et al
    In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome.
    Gut. 2016 May 24. pii: gutjnl-2015-311000. doi: 10.1136/gutjnl-2015-311000.
    PubMed     Text format     Abstract available


  38. WANG L, Xia J, Wang L, Wang Y, et al
    Experimental infection of rabbits with genotype 3 hepatitis E virus produced both chronicity and kidney injury.
    Gut. 2016 May 10. pii: gutjnl-2016-312023. doi: 10.1136/gutjnl-2016-312023.
    PubMed     Text format    


  39. BLAYA D, Coll M, Rodrigo-Torres D, Vila-Casadesus M, et al
    Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation.
    Gut. 2016 May 10. pii: gutjnl-2015-311314. doi: 10.1136/gutjnl-2015-311314.
    PubMed     Text format     Abstract available


    April 2016
  40. FISCHER J, Weber AN, Bohm S, Dickhofer S, et al
    Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection.
    Gut. 2016 Apr 21. pii: gutjnl-2015-310239. doi: 10.1136/gutjnl-2015-310239.
    PubMed     Text format     Abstract available


  41. SCOTT N, McBryde ES, Thompson A, Doyle JS, et al
    Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.
    Gut. 2016 Apr 12. pii: gutjnl-2016-311504. doi: 10.1136/gutjnl-2016-311504.
    PubMed     Text format     Abstract available


  42. BOYD A, Bottero J, Lacombe K
    The gamma-glutamyl transpeptidase-to-platelet ratio as a predictor of liver fibrosis in patients co-infected with HBV and HIV.
    Gut. 2016;65:718-20.
    PubMed     Text format    


    March 2016
  43. SAYED IM, Verhoye L, Cocquerel L, Abravanel F, et al
    Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver.
    Gut. 2016 Mar 22. pii: gutjnl-2015-311109. doi: 10.1136/gutjnl-2015-311109.
    PubMed     Text format     Abstract available


  44. ZHAO XL, Yang JR, Lin SZ, Ma H, et al
    Serum viral duplex-linear DNA proportion increases with the progression of liver disease in patients infected with HBV.
    Gut. 2016;65:502-11.
    PubMed     Text format     Abstract available


    February 2016
  45. RAJORIYA N, Feld JJ
    One small SNP for receptor virus entry, one giant leap for hepatitis B?
    Gut. 2016 Feb 18. pii: gutjnl-2015-311029. doi: 10.1136/gutjnl-2015-311029.
    PubMed     Text format    


  46. JAMIL KM, Hydes TJ, Cheent KS, Cassidy SA, et al
    STAT4-associated natural killer cell tolerance following liver transplantation.
    Gut. 2016 Feb 17. pii: gutjnl-2015-309395. doi: 10.1136/gutjnl-2015-309395.
    PubMed     Text format     Abstract available


  47. VERGIS N, Khamri W, Beale K, Sadiq F, et al
    Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidase.
    Gut. 2016 Feb 9. pii: gutjnl-2015-310378. doi: 10.1136/gutjnl-2015-310378.
    PubMed     Text format     Abstract available


  48. WIESER V, Adolph TE, Enrich B, Kuliopulos A, et al
    Reversal of murine alcoholic steatohepatitis by pepducin-based functional blockade of interleukin-8 receptors.
    Gut. 2016 Feb 8. pii: gutjnl-2015-310344. doi: 10.1136/gutjnl-2015-310344.
    PubMed     Text format     Abstract available


  49. VISVANATHAN K, Dusheiko G, Giles M, Wong ML, et al
    Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders.
    Gut. 2016;65:340-50.
    PubMed     Text format     Abstract available


  50. XIN J, Ding W, Hao S, Chen X, et al
    Serum macrophage inflammatory protein 3alpha levels predict the severity of HBV-related acute-on-chronic liver failure.
    Gut. 2016;65:355-7.
    PubMed     Text format    


    January 2016
  51. POH Z, Shen L, Yang HI, Seto WK, et al
    Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B.
    Gut. 2016 Jan 19. pii: gutjnl-2015-310818. doi: 10.1136/gutjnl-2015-310818.
    PubMed     Text format    


  52. SERTI E, Park H, Keane M, O'Keefe AC, et al
    Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNalpha.
    Gut. 2016 Jan 4. pii: gutjnl-2015-310033. doi: 10.1136/gutjnl-2015-310033.
    PubMed     Text format     Abstract available


  53. STOCKDALE AJ, Phillips RO, Geretti AM
    The gamma-glutamyl transpeptidase to platelet ratio (GPR) shows poor correlation with transient elastography measurements of liver fibrosis in HIV-positive patients with chronic hepatitis B in West Africa. Response to: 'The gamma-glutamyl transpeptida
    Gut. 2016 Jan 4. pii: gutjnl-2015-311133. doi: 10.1136/gutjnl-2015-311133.
    PubMed     Text format    


    December 2015
  54. VARCHETTA S, Mele D, Lombardi A, Oliviero B, et al
    Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection.
    Gut. 2015 Dec 16. pii: gutjnl-2015-310327. doi: 10.1136/gutjnl-2015-310327.
    PubMed     Text format     Abstract available


  55. HU HH, Liu J, Lin YL, Luo WS, et al
    The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B.
    Gut. 2015 Dec 7. pii: gutjnl-2015-310686. doi: 10.1136/gutjnl-2015-310686.
    PubMed     Text format     Abstract available


    November 2015
  56. SUREAU C
    A unique monoclonal antibody for therapeutic use against chronic hepatitis B: not all antibodies are created equal.
    Gut. 2015 Nov 26. pii: gutjnl-2015-310978. doi: 10.1136/gutjnl-2015-310978.
    PubMed     Text format    


  57. PRENTOE J, Verhoye L, Velazquez Moctezuma R, Buysschaert C, et al
    HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice.
    Gut. 2015 Nov 20. pii: gutjnl-2015-310300. doi: 10.1136/gutjnl-2015-310300.
    PubMed     Text format     Abstract available


    October 2015
  58. NAHON P, Lescat M, Layese R, Bourcier V, et al
    Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort).
    Gut. 2015 Oct 28. pii: gutjnl-2015-310275. doi: 10.1136/gutjnl-2015-310275.
    PubMed     Text format     Abstract available


    July 2015
  59. KENG CT, Sze CW, Zheng D, Zheng Z, et al
    Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection.
    Gut. 2015 Jul 6. pii: gutjnl-2014-307856. doi: 10.1136/gutjnl-2014-307856.
    PubMed     Text format     Abstract available


    June 2015
  60. LEMOINE M, Shimakawa Y, Nayagam S, Khalil M, et al
    The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa.
    Gut. 2015 Jun 24. pii: gutjnl-2015-309260. doi: 10.1136/gutjnl-2015-309260.
    PubMed     Text format     Abstract available


  61. ZHANG DY, Goossens N, Guo J, Tsai MC, et al
    A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection.
    Gut. 2015 Jun 4. pii: gutjnl-2015-309655. doi: 10.1136/gutjnl-2015-309655.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: